Tilt Investment Management Holdings PBC Cuts Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Tilt Investment Management Holdings PBC cut its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 24.3% in the fourth quarter, Holdings Channel reports. The fund owned 1,414 shares of the medical equipment provider’s stock after selling 453 shares during the quarter. Tilt Investment Management Holdings PBC’s holdings in Intuitive Surgical were worth $477,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. RB Capital Management LLC lifted its position in shares of Intuitive Surgical by 4.4% in the 1st quarter. RB Capital Management LLC now owns 1,735 shares of the medical equipment provider’s stock worth $523,000 after purchasing an additional 73 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Intuitive Surgical by 0.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 946,709 shares of the medical equipment provider’s stock worth $285,603,000 after buying an additional 5,233 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in Intuitive Surgical by 2.3% during the first quarter. Baird Financial Group Inc. now owns 21,089 shares of the medical equipment provider’s stock worth $6,362,000 after buying an additional 481 shares during the period. Brown Brothers Harriman & Co. boosted its position in Intuitive Surgical by 576.7% during the 1st quarter. Brown Brothers Harriman & Co. now owns 406 shares of the medical equipment provider’s stock valued at $122,000 after acquiring an additional 346 shares in the last quarter. Finally, Covestor Ltd boosted its position in Intuitive Surgical by 50.4% during the 1st quarter. Covestor Ltd now owns 418 shares of the medical equipment provider’s stock valued at $126,000 after acquiring an additional 140 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Intuitive Surgical

In related news, VP Fredrik Widman sold 5,041 shares of the business’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $397.07, for a total value of $2,001,629.87. Following the sale, the vice president now owns 110 shares in the company, valued at approximately $43,677.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Intuitive Surgical news, EVP Myriam Curet sold 4,318 shares of the business’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $370.15, for a total value of $1,598,307.70. Following the completion of the transaction, the executive vice president now owns 189 shares in the company, valued at $69,958.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Fredrik Widman sold 5,041 shares of Intuitive Surgical stock in a transaction on Friday, March 15th. The shares were sold at an average price of $397.07, for a total value of $2,001,629.87. Following the completion of the transaction, the vice president now owns 110 shares of the company’s stock, valued at $43,677.70. The disclosure for this sale can be found here. Insiders sold a total of 248,418 shares of company stock worth $95,927,097 over the last ninety days. Company insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

ISRG has been the subject of several research reports. Truist Financial boosted their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. StockNews.com cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Citigroup raised their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Barclays upped their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research note on Thursday, January 25th. Finally, Wells Fargo & Company raised their target price on shares of Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research note on Friday, January 19th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average target price of $375.70.

Intuitive Surgical Trading Down 0.2 %

NASDAQ ISRG traded down $0.58 during trading hours on Thursday, reaching $373.59. The company had a trading volume of 1,379,025 shares, compared to its average volume of 1,631,836. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The stock has a market capitalization of $132.42 billion, a P/E ratio of 74.39, a price-to-earnings-growth ratio of 5.88 and a beta of 1.36. The stock has a 50-day moving average of $387.56 and a 200 day moving average of $342.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported $1.60 EPS for the quarter, topping the consensus estimate of $1.48 by $0.12. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The firm had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same period in the prior year, the business posted $0.91 EPS. The business’s revenue for the quarter was up 16.6% compared to the same quarter last year. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.